Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
IQVIA Holdings (IQV): Form 4 shows director equity activity. Director Colleen A. Goggins acquired 181 deferred share units on 11/05/2025 at $210.12 each. Following the transaction, she holds 4,702 deferred share units directly.
Each deferred share converts 1-for-1 into IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, settlement occurs when the director ceases service, upon a change in control, or upon death. The deferred shares have no expiration date.
IQVIA Holdings Inc. (IQV) reported an insider equity change as a director acquired 193 deferred shares on 11/05/2025 at a recorded derivative security price of $210.12, according to a Form 4 filing.
Each deferred share is convertible into one share of common stock upon settlement, which occurs when the director ceases to serve, upon a change in control of the company, or upon death, with no expiry date. Following this transaction, the director beneficially owned 4,063 deferred share units directly.
IQVIA Holdings (IQV): Director Form 4 update. Director John G. Danhakl reported acquiring 158 deferred shares on 11/05/2025 at a price of $210.12 per unit. Following this transaction, he beneficially owned 2,772 derivative securities.
These deferred shares convert into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, settlement occurs when the director leaves the board, upon a change in control of the company, or upon the director’s death. The deferred shares have no expiration date. Ownership is reported as direct.
IQVIA Holdings Inc. appointed William G. Kaelin Jr., M.D. to its Board of Directors on November 5, 2025. The Board determined that Dr. Kaelin meets the New York Stock Exchange definition of an independent director. In connection with the appointment, he is expected to enter into the company’s standard indemnification agreement for non-management directors and will participate in the non-employee director compensation program described under “Director Compensation” in the proxy statement dated February 28, 2025. The company announced the appointment via a press release attached as Exhibit 99.1.
IQVIA Holdings Inc. (IQV): Executive Vice President and General Counsel Eric Sherbet reported insider transactions on 10/29/2025. He exercised stock appreciation rights at $131.82 to acquire 10,000 shares, then sold 4,000 shares at a weighted average price of $219.70 (ranging from $219.66 to $219.92) and 6,000 shares at $219.72. Following these trades, he directly owns 21,108 shares. The SARs related to 10,000 underlying shares (exercisable since 02/13/2022, expiring 02/13/2029), with 8,436 derivative securities remaining beneficially owned.
IQVIA (IQV) insider transaction: On 10/29/2025, Chairman, Chief Executive Officer & President Ari Bousbib exercised stock appreciation rights for 77,592 shares at an exercise price of $59.90, then sold shares in multiple open‑market transactions. The reported weighted average sale prices ranged from $216.70 to $222.27 across the disclosed trade batches.
Following these transactions, Bousbib beneficially owned 807,163 shares directly. He also reported 543,302 shares held indirectly by a trust.
IQV (issuer) — Notice of proposed sale under Form 144. A shareholder filed to sell up to 56,557 shares of common stock, with an aggregate market value of $12,460,983.24. The approximate sale date listed is 10/29/2025, and the shares are listed on the NYSE. Morgan Stanley Smith Barney LLC is named as the broker.
The securities were acquired via Stock Appreciation Rights on 10/29/2025, with 56,557 shares indicated and cash noted as the nature of payment. The filing lists 170,300,000 shares outstanding, providing context for the potential sale size.
IQVIA Holdings (IQV) filed a Form 144 notice indicating an intended sale of 4,000 shares of common stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $878,819.60 for the planned sale, with an approximate sale date of 10/29/2025 on the NYSE.
The shares were acquired on 10/29/2025 via Stock Appreciation Rights from the issuer, with a stated amount acquired of 4,000 and cash as the nature of payment. The filing also notes 170,300,000 shares outstanding for context. Form 144 is a notice of proposed sale by an affiliate or other reporting person and does not, by itself, guarantee that a sale will occur.
IQVIA Holdings Inc. reported third‑quarter results with steady growth and active balance sheet management. Q3 2025 revenue was $4.1 billion versus $3.896 billion a year ago, and diluted EPS was $1.93 compared with $1.55. Segment revenue reached $1.631 billion in Technology & Analytics Solutions, $2.260 billion in Research & Development Solutions, and $209 million in Contract Sales & Medical Solutions. Q3 income from operations was $553 million. For the first nine months, revenue totaled $11.946 billion and diluted EPS was $4.86.
Operating cash flow for the nine months was $1.919 billion, supporting $1.032 billion of share repurchases (6.4 million shares). The company issued $2.0 billion of 6.250% senior notes due 2032 and amended its credit facilities, including a $1.985 billion Term B-5 loan to refinance prior tranches. Total debt principal was $15.034 billion and cash was $1.814 billion at quarter‑end. Remaining performance obligations were $34.4 billion, with about 30% expected to convert within 12 months. Goodwill increased to $15.948 billion, reflecting acquisitions. Common shares outstanding were 170.3 million as of October 20, 2025. Legal disputes with Veeva were fully resolved in August 2025 with no payment by either party.
IQVIA Holdings Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The full text of the release was posted on the company’s website and is included as Exhibit 99.1. Pursuant to General Instruction B.2, the Item 2.02 information is furnished, not filed, and is not subject to Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.